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1061-86 Underutilization of Oral Anticoagulation for Atrial 
Fibrillation in Survivors of Acute Myocardial Infarction 
Influences Long-Term Mortality
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital, Linkoping, Sweden, 
UCR, University Hospital, Uppsala, Sweden
Background: Oral anticoagulation (OAC) treatment is generally recommended in
patients with atrial fibrillation (AF) and coronary artery disease. We investigated the pre-
scription of OAC in patients discharged alive with atrial fibrillation after an acute myocar-
dial infarction (AMI) and the influence of OAC treatment on 1-year mortality.
Methods: Prospective cohort study using data from the Register of Information and
Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) on patients
admitted to the coronary care units of 72 Swedish hospitals 1995-2001. All 11141
patients with first registry-recorded AMI who were discharged with atrial fibrillation were
included. 1-year mortality data were obtained from the Swedish National Cause of Death
Register.
Results: Only 21 %(n=2384) of the patient were prescribed OAC while 79% (n=8757)
were not. At 1 year unadjusted mortality was 26% (2301 deaths) in the no-OAC group
and 20% (481 deaths) in the OAC treated group. Also in Cox regression analysis adjust-
ing for 36 confounding factors OAC treatment was associated with reduction in 1-year
mortality (relative risk, 0.66; 95% confidence interval 0.57-0.76; P<0.001) in hospital sur-
vivors of AMI with AF. This reduction of mortality was similar among all subgroups based
on age, sex, baseline characteristics, previous disease manifestations, and medications. 
Conclusions: In daily clinical practise OAC is only given to a minority (21%) of AMI
patients with AF despite that OAC is associated with a 34% relative reduction in 1-year
mortality. The results emphasizes the importance of OAC treatment for AF after AMI.
1061-87 Effects of Zofenopril on Ischemia Following Myocardial 
Infarction: The SMILE Study
Claudio Borghi, Ettore Ambrosioni, St. Orsola-Malpighi Hospital, Bologna, Italy
Background. Zofenopril calcium is an ACE-inhibitor with a SH-moiety which showed to be
effective in pts with MI. Aim of study was to investigate anti-ischemic effects of zofenopril
(Z) in post-MI pts with normal LV function.
Methods. A multicentre, randomized, double-blind, placebo-controlled study was per-
formed in 349 post-MI pts with LV ejection fraction (LVEF) > 40% treated with Z (30-60
mg/day) or placebo in addiction to recommended therapy for a period of 6 months. Pri-
mary objective was 6-month combined occurrence of: new onset of significant ECG
abnormalities, ST-T abnormalities during 48-hour ambulatory ECG monitoring, recurrent-
MI, need of revascularization procedures for angina. Secondary objectives were 6-month
mortality and morbidity, new onset of post-MI angina, clinical and ECG response to exer-
cise test, rate of CHF (NYHA class II-IV).
Results. One hundred seventy-seven pts have been randomly allocated to Z and 172 to
placebo. Fifteen pts have been excluded from analysis because of protocol violation or
lost at follow-up. At baseline the two populations were comparable for demographic pro-
file, prevalence of cardiovascular risk factors, MI size and location, LVEF (54.4+/- vs
53.3+/-9), BP and concomitant drug therapy. ST depression on ambulatory ECG
occurred in 10.7% of Z treated pts and in 22.2% of those taking placebo (2p=0.027).
Peak ST depression was 1.57 mm vs 2.57 mm in pts treated with Z and placebo respec-
tively (2p=0.038). Mean duration of ST depression in the same populations was 7.6 min
and 25.2 min (2p=0.020). In response to exercise test a lesser proportion of patients
treated with Z complained anginal pain (4.7 vs 14.3%; 2p=0.017), significant ST depres-
sion (14.2 vs 26.7%; 2p=0.024) and relevant arrhythmias (3.8 vs 10.5%; p=0.048). Time
to ST depression during exercise was increased (6.93 vs 4.42 min; 2p=0.024) and peak
ST depression (1.21 vs 1.95 mm; p=0.001) was reduced in Z treated patient. Major car-
diovascular events were evenly distributed between study populations with a lesser rate
of progression of CHF in Z pts.
Conclusions. This randomized, placebo controlled clinical trial support the anti-ischemic
role of Z when given to pts with normal LV function following acute MI.
1061-88 Causes of Death in Patients With ST Elevation 
Myocardial Infarction Treated With Fibrinolysis
Amir Kashani, Elliott M. Antman, David A. Morrow, Robert P. Giugliano, TIMI-Study 
Group; Brigham & Women's Hospital, Boston, MA, Rochester General Hospital, 
Rochester, NY
Background: Recent developments in reperfusion pharmacologic therapy have not fur-
ther reduced mortality in ST-Elevation myocardial infarction (ST-EMI). We explored the
causes of death in a recent ST-EMI megatrial to better understand why patients die fol-
lowing fibrinolysis.
Methods: We evaluated the investigator reported causes of death in 15,078 patients
enrolled in InTIME-II (lanoteplase vs alteplase).
Results: There were 913 deaths (6.1% mortality) during the index hospitalization, 93
deaths (0.7% mortality) between hospital discharge and 30 days, and 303 deaths (2.2%
mortality) between 31 and 180 days. The six leading causes of early (< 30 days) death
(n=1006 deaths, 6.7% mortality) were congestive heart failure (CHF) (30%), recurrent MI
(20%), cardiac rupture (17%), intracranial hemorrhage (9%), other cardiovascular (9%),
and dysrhythmia (7%). Between 30 days and 6 months the leading causes of death were
recurrent MI (20%), other non-cardiac (20%), and CHF (18%). Among patients with
shock or severe CHF (n=1801, 11.9% incidence) during the index admission, CHF
accounted for 53% of the early deaths.
Conclusions: In the modern fibrinolytic era, 30% of early deaths are due to CHF. Among
patients developing early shock or severe heart failure, CHF accounted for more than half
of the deaths through 30 days. These findings suggest that attempts to reduce early mor-
tality after fibrinolysis should include both therapies that improve myocardial salvage, and
more aggressive treatment of post-MI CHF.
1061-89 Trends in Non-ST-Segment Elevation Myocardial 
Infarction Care: The National Acute Myocardial 
Infarction Project 1998-2001
JoAnne M. Foody, Deron H. Galusha, Saif S. Rathore, Frederick A. Masoudi, Edward P. 
Havranek, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background: In 2000, the ACC/AHA published guidelines for patients with NSTEMI.
Whether release of these guidelines has been associated with increasing use of evi-
dence-based therapies is unknown.
Methods: In two national cohorts of 31,399 and 31,759 older patients hospitalized
between 1998-9 and 2000-1 respectively with confirmed AMI, we identified patients who
presented with NSTEMI (n=19,278 in 1998-9 and n=21,007 in 2000-1). We assessed
change in quality of care using 6 quality of care indicators: admission use of aspirin,
admission use of beta blockers, discharge prescription of aspirin, discharge prescription
of beta blockers, ACE inhibitors and lipid lowering in ‘ideal candidates’ without treatment
specific contraindications.
Results: An increasing proportion of older patients admitted with AMI had NSTEMI
(61.4% in 1998- 9 and 66.6% in 2000-1). From 1998-9 to 2000-1, increases were seen in
admission use of aspirin and beta-blockers as well as discharge prescription of aspirin,
beta blockers, ACE Inhibitors and lipid lowering therapy.
Conclusions: Two thirds of Medicare beneficiaries hospitalized with AMI in 2000-1 pre-
sented with NSTEMI. Only modest advances were made nationally in the care of older
patients with NSTEMI and a significant proportion of patients with NSTEMI do not
receive evidence-based care. Further interventions are required to improve care for the
growing numbers of patients presenting with NSTEMI.
1061-90 Effects of Mechanical Left Ventricular Unloading on 
Endothelin-1 Release and Apoptosis
Hela C. Achour, Fernando Boccalandro, Maximilian L. Buja, Yong-Jian Geng, James 
Amirian, Patty Felli, Richard W. Smalling, University of Texas Health Science Center, 
Houston, TX
Background: Endothelin-1 (ET) and apoptosis may play a pivotal role in mediating tis-
sue injury during myocardial ischemia and reperfusion. Left ventricular (LV) unloading
during myocardial infarction has been shown to limit reperfusion injury and infarct size.
The purpose of this study was to determine the prevention of or reversibility of these pro-
cesses under mechanical LV assistance.
Methods: Six dogs subjected to 2 hours of left anterior descending coronary artery
(LAD) occlusion followed by 4 hours of reperfusion were randomly assigned to: 1/ a con-
trol group (n= 3) with sham LV assistance on, 2/ a treated group (n= 3) with mechanical
LV assistance on, using a trans-valvular LV assist device, initiated 10 minutes prior to
reperfusion. Serial ET levels were obtained from the coronary sinus and aortic blood and
measured by radio-immunoassay. The extent of contraction band necrosis in the
ischemic area defined by Evan's blue dye was determined by quantitative histology. Car-
diomyocyte apoptosis was determined by terminal deoxynucleotidyl transferase-medi-
ated dUTP nick-end labeling (TUNEL) staining.
Results: A similar increase in aortic and coronary sinus blood ET was observed in both
groups during LAD occlusion. A significant trans-cardiac increase in ET levels was
present in the control group 10 minutes after reperfusion whereas no increase occurred
Causes of Death
Variable Inhospital Death 30 Days Death 31-180 Days Death
(N=913) (N=1006) (N=303)
CHF 30.0 29.6 17.5
Recurrent MI 20.2 20.2 19.8
Rupture 18.5 16.9 0.3
Intracranial Hemorrhage 10.0 9.0 0.7
Other Cardiovascular 8.8 8.7 8.3
Dysrhythmia 6.6 6.9 8.6
Other Non-Cardiac 3.5 3.9 19.8
Unobserved 1.3 3.1 9.9
Unknown 1.2 1.7 15.2
Numbers in table represent percentages of death.
Trends In AMI Care
1998-1999 Rate
(%)
2000-2001 Rate
(%)
Early aspirin 81.9 84.0
Discharge aspirin 84.0 85.5
Early beta blocker 60.6 66.8
Discharge Beta blocker 70.6 77.8
Discharge ACE inhibitor 66.6 72.9
Discharge Lipid lowering 52.1 69.4
